ENGN 주가 차트
ENGN 주가 예측
enGene Therapeutics Inc
$1.72
-80.56%
$-7.13
종가: May 07, 16:00:00 GMT-4
$1.72
0.02%
$0
애프터마켓: May 07, 20:00:00 GMT-4
뒤로
enGene Therapeutics Inc (ENGN) 주가 예측
주요 통계
이전 종가
$8.85
시가
$2.14
일일 범위
$1.7 - $2.24
52주 범위
$1.72 - $12.25
거래량
23.4M
평균 거래량
401.2K
배당수익률
--
EPS(TTM)
-2.25
시가총액
$115.2M
ENGN란 무엇인가요?
enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
